Literature DB >> 1698237

Fludarabine monophosphate for prolymphocytic leukaemia.

O P Smith, A B Mehta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1698237     DOI： 10.1016/0140-6736(90)93293-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 2.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 3.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Fludarabine phosphate for the treatment of low grade lymphoid malignancy.

Authors:  J S Whelan; C L Davis; S Rule; M Ranson; O P Smith; A B Mehta; D Catovsky; A Z Rohatiner; T A Lister
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.